Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Rheumatology · Tumor Necrosis Factor 1 Associated Periodic Syndrome

Monitoring and Long-Term Health with TRAPS

At a Glance

TRAPS can cause silent inflammation between flares, raising the risk of AA amyloidosis and kidney damage. Regular SAA, CRP, ESR, kidney function, blood pressure, and urine testing helps identify ongoing inflammation early; children also need growth and development tracking.

While the immediate goal of treating Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) is to stop the pain and fever of a flare, the most critical long-term goal is protecting your organs from sustained inflammation. Even when you feel completely healthy between flares, your immune system may still be producing high levels of inflammatory proteins that can cause silent damage over time [1][2].

The Risk of AA Amyloidosis

The most serious long-term complication of TRAPS is AA amyloidosis. This condition occurs when your body produces too much of a protein called Serum Amyloid A (SAA) during periods of uncontrolled inflammation [3]. If SAA levels remain persistently high, the protein can misfold and form “amyloid fibrils”—clumps of protein that deposit in your organs [1].

These deposits most commonly build up in the kidneys. Over time, this buildup can cause:

  • Proteinuria: Protein leaking into the urine, which is often the first warning sign [4].
  • Nephrotic Syndrome: Severe swelling (edema) and kidney dysfunction.
  • Kidney Failure: In severe, untreated cases, the kidneys may stop working entirely, requiring dialysis or a transplant [4][5].

It is important to understand that amyloidosis risk is highly variable. Historical data showed that 16% to 25% of untreated patients with high-penetrance (structural/cysteine) variants developed AA amyloidosis [6][2]. However, your personal risk depends on your specific variant, your ancestry, and how well your inflammation is controlled. Modern therapies that effectively lower SAA levels substantially reduce this risk, though they do not eliminate the need for monitoring [6].

The Importance of Routine Monitoring

Because you cannot “feel” high SAA levels or early kidney damage, regular laboratory testing is essential. Most international consensus points recommend long-term monitoring of inflammation and organ health [7][8].

Monitoring frequency should be individualized. While some stable patients may have labs drawn every 6 months, you will likely need more frequent tests during active flares or after changing medications. A typical monitoring plan includes:

  1. Serum Amyloid A (SAA): The most direct marker for amyloidosis risk (though it may not be available in every laboratory) [1][9].
  2. C-Reactive Protein (CRP) and ESR: General markers of systemic inflammation [10][2].
  3. Comprehensive Kidney Function Tests: This includes serum creatinine to calculate your estimated glomerular filtration rate (eGFR), and routine blood pressure checks.
  4. Urine Testing: Urinalysis or a quantitative urine protein/albumin-to-creatinine ratio to detect early protein leakage [11][4].

Note: A normal symptom report or a single normal SAA result does not guarantee that organ damage is completely absent, which is why routine medical evaluation is necessary.

Special Considerations for Children

In children, chronic inflammation can interfere with normal growth and development, sometimes causing slowed growth velocity [12]. Pediatric long-term care should include tracking height, weight, and Body Mass Index (BMI) on a growth chart to ensure the child stays on their expected curve, alongside monitoring pubertal development and school performance [12].

Common questions in this guide

Why is AA amyloidosis a long-term concern for people with TRAPS?
AA amyloidosis develops when ongoing inflammation keeps a protein called Serum Amyloid A high, allowing abnormal protein deposits to build up in organs, especially the kidneys. It can first cause protein in the urine and swelling, and severe cases can lead to kidney failure. Good inflammation control and regular testing can lower the risk.
How often should I have tests for TRAPS?
The schedule should be personalized with your care team. Some stable people may have testing about every six months, while active flares or a medication change may require more frequent checks. Testing commonly includes inflammation markers, kidney blood tests, blood pressure, and urine protein.
Can TRAPS cause kidney damage even when I feel well?
Yes. Inflammation and early kidney damage may not cause noticeable symptoms between flares, so feeling well or having one normal Serum Amyloid A (SAA) result does not rule out risk. Regular blood and urine testing helps detect changes earlier.
What does a Serum Amyloid A test show in TRAPS?
Serum Amyloid A, or SAA, is a blood marker that reflects inflammation and is used to estimate the risk of AA amyloidosis. Persistently high levels suggest that inflammation may not be fully controlled, even if symptoms are absent. Your clinician uses the result with other blood, urine, and kidney tests.
What kidney tests are recommended for TRAPS monitoring?
Urinalysis or a urine protein-to-creatinine or albumin-to-creatinine ratio can find early protein leakage. Blood creatinine is used to estimate kidney filtration, called the estimated glomerular filtration rate (eGFR), and regular blood pressure checks can identify kidney stress. The exact schedule depends on your inflammation and medical history.
How should children with TRAPS be monitored?
Children should have height, weight, and body mass index tracked on a growth chart, along with puberty and school progress. Their care team may also monitor inflammation, kidney function, blood pressure, and urine protein. The testing schedule should be tailored to the child's disease activity.
How does my TNFRSF1A variant affect my risk of AA amyloidosis?
Risk varies with the specific TNFRSF1A variant, ancestry, and how consistently inflammation is controlled. High-penetrance structural or cysteine variants have been associated with greater risk, but a clinician who knows your history is needed to estimate your individual risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my most recent Serum Amyloid A (SAA) level, and is it within the target range to prevent long-term damage?
  2. 2.Based on my specific TNFRSF1A mutation and disease history, what is my individual risk for developing AA amyloidosis?
  3. 3.How frequently should I have my urine checked for protein, and what other kidney function tests (like eGFR) do you recommend?
  4. 4.If my inflammatory markers remain high even when I feel fine, should we consider adjusting my medication dose or frequency?
  5. 5.For my child, how often should we be tracking their growth and development on a growth chart to ensure TRAPS is not affecting their progress?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.

    Cudrici C, Deuitch N, Aksentijevich I

    International journal of molecular sciences 2020; (21(9)) doi:10.3390/ijms21093263.

    PMID: 32380704
  2. 2

    Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.

    Gaggiano C, Vitale A, Obici L, et al.

    Mediators of inflammation 2020; (2020()):8562485 doi:10.1155/2020/8562485.

    PMID: 32831641
  3. 3

    Kidney Involvement in Autoinflammatory Diseases.

    Zhang C, Peng J, Liu Z, Zhou Q

    Kidney diseases (Basel, Switzerland) 2023; (9(3)):157-172 doi:10.1159/000529917.

    PMID: 37497206
  4. 4

    Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.

    Delaleu J, Deshayes S, Rodrigues F, et al.

    Rheumatology (Oxford, England) 2021; (60(12)):5775-5784 doi:10.1093/rheumatology/keab252.

    PMID: 33715002
  5. 5

    Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure.

    Coutinho J, Chorão RS, Oliveira M, Santos CR

    Case reports in nephrology 2019; (2019()):6819476 doi:10.1155/2019/6819476.

    PMID: 31007959
  6. 6

    INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry.

    Papa R, Lane T, Minden K, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(2)):783-791.e4 doi:10.1016/j.jaip.2020.10.053.

    PMID: 33181346
  7. 7

    Recommendations for the management of autoinflammatory diseases.

    ter Haar NM, Oswald M, Jeyaratnam J, et al.

    Annals of the rheumatic diseases 2015; (74(9)):1636-44 doi:10.1136/annrheumdis-2015-207546.

    PMID: 26109736
  8. 8

    The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

    Romano M, Arici ZS, Piskin D, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(7)):1102-1121 doi:10.1002/art.42139.

    PMID: 35621220
  9. 9

    Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial.

    Gattorno M, Obici L, Penadés IC, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(2)):304-312 doi:10.1002/art.42695.

    PMID: 37668289
  10. 10

    Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

    Vitale A, Obici L, Cattalini M, et al.

    Frontiers in medicine 2021; (8()):668173 doi:10.3389/fmed.2021.668173.

    PMID: 34307404
  11. 11

    Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

    Chen Y, Huang X, Zheng S, et al.

    Clinical rheumatology 2018; (37(5)):1433-1438 doi:10.1007/s10067-018-4023-4.

    PMID: 29450850
  12. 12

    Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation.

    Klinaki E, Nezos A, Tzioufas AG, et al.

    Cureus 2020; (12(10)):e10766 doi:10.7759/cureus.10766.

    PMID: 33154839

This page explains long-term TRAPS monitoring and AA amyloidosis risk for education; it does not replace medical advice. Your rheumatology and kidney-care team can tailor testing and treatment to you or your child.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.